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Tranexamic acid for postpartum haemorrhage: a major 
advance
The WOMAN trial was a massive, international, 
double‑blind, placebo‑controlled study of the effective‑
ness of tranexamic acid for the treatment of bleeding 
after childbirth. The clinical results have been eagerly 
anticipated and were published last year.1 The Lancet 
Global Health has now published the results of a cost‑
effectiveness analysis of data from the WOMAN trial.2 
Together, these results show a clean sweep for tranexamic 
acid in the treatment of postpartum haemorrhage: not 
only does it reduce deaths from bleeding by 20% (1·9% 
with placebo vs 1·5% with tranexamic acid, risk ratio 
0·81, 95% CI 0·65–1·00; p=0·045) but it is also cost‑
effective in countries with a high baseline risk of deaths 
from postpartum haemorrhage. As a consequence, WHO 
postpartum haemorrhage guidelines have already been 
updated to include tranexamic acid.3
However, there are some puzzling aspects to 
these results. First, how does an intervention reduce 
bleeding‑related deaths and laparotomies but have 
no effect on any other blood‑loss‑related morbidity? 
If tranexamic acid reduced blood loss from postpartum 
haemorrhage in general, one would surely see an effect 
on the morbidity of all women in the study, not just 
those who had those two complications. It is true 
that tranexamic acid was given at the same time as 
many decisions were being made about their care. This 
approach meant that the outcomes observed were 
really baseline characteristics since they could not be 
affected by tranexamic acid. But other outcomes can 
only be collected at the end of the process (eg, time 
in hospital and quality of life at discharge), and there 
was no reduction in either of these. The only benefits 
of tranexamic acid are on death from bleeding and on 
laparotomy for bleeding, suggesting that there was 
no benefit of tranexamic acid for most women with 
postpartum haemorrhage.
A second question is why the maximum reduction 
in mortality was seen in women recruited 1–3 h after 
birth, even though most women were recruited in the 
first postnatal hour. And third, why was the number of 
brace sutures significantly greater in the tranexamic acid 
group than in the placebo group? Is this result simply a 
statistical blip—or could it be more?
The answer to all three questions might be found 
in the peculiarities of postpartum haemorrhage. 
There are multiple underlying causes of postpartum 
haemorrhage: atonic uterus is the most common cause, 
but retained placental tissue and genital tract trauma 
(either iatrogenic or caused by childbirth) are both 
also common. Treatments for postpartum haemorrhage 
generally address just one of these causes. Coagulopathy 
is also on the list of causes of postpartum haemorrhage, 
but is rarely the primary cause. This because the main 
mechanism for uterine haemostasis after childbirth is 
a uterine contraction compressing the uterine vessels 
rather than clotting. Thus, even in women with marked 
clotting disorders, 40–70% have completely normal 
postpartum blood loss.4 Conversely, there is no evidence 
that women with a tendency for increased clotting 
through inherited thrombophilias are less likely than 
other women to have postpartum haemorrhage.5 
It would not be surprising therefore if tranexamic acid 
had no effect on normal postnatal blood loss. Nor would 
we expect the drug to have much effect on massive 
haemorrhage where large open vessels are pouring with 
blood. What we might expect to see, however, is an 
effect on blood loss in a subgroup of women who are 
bleeding vaginally or into the abdomen from smaller 
lacerations or trauma. In these women, the primary 
haemostatic mechanism is spontaneous clotting within 
the bleeding vessel.
The results from the WOMAN trial are entirely 
consistent with an effect on this subgroup of women 
who have postpartum haemorrhage with small but 
deadly spontaneous or iatrogenic lacerations to the 
genital tract. These lacerations tend to cause oozing 
and trickling, usually following caesarean section, with 
their clinical effects not being obvious until an hour or 
two after birth because of the slow rate of blood flow. 
The only treatment available is surgery (usually repeat 
laparotomy), a highly dangerous operation in already 
compromised women, especially in under‑resourced 
settings with limited senior anaesthetic or surgical 
cover. In the WOMAN trial, most laparotomies for 
bleeding were done in women who had given birth by 
caesarean section, even though only a quarter of women 
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gave birth that way. The maximum effect was seen 
in women whose postpartum haemorrhage became 
evident 1–3 h after birth—the very time when oozing 
and trickling lacerations typically cause postpartum 
women to collapse on postnatal wards.
In the WOMAN trial, tranexamic acid appeared to 
reduce deaths irrespective of whether the cause of 
postpartum haemorrhage was believed to be atony 
or another reason. But in clinical practice, diagnosis 
of atony is highly subjective, especially at caesarean 
section or laparotomy. If there is bleeding, the surgeon 
will seek out the source of blood loss and treat it. If this 
is a generalised ooze, the surgeon will place additional 
sutures to that area and then close the abdomen. If there 
is no ooze, however, the surgeon will do one of the only 
other interventions possible before hysterectomy: a 
brace suture. Thus, a reduction in oozing results in an 
increase in use of brace sutures.
A final puzzle for some readers might be that, 
although tranexamic acid is stated to significantly 
reduce maternal death from bleeding, the 95% CIs 
include 1·00. By definition, this outcome indicates 
a possibility of no effect. Purists will state that the 
hypothesis that tranexamic acid reduces deaths from 
bleeding should have been rejected. There is, however, 
a move away from using the arbitrary cutoff of 95% for 
CIs, which dichotomises results into being significant 
or not significant. Led by the Cochrane Collaboration,6 
the aim is to look at the results of studies holistically, 
seeking to gain meaning from overall patterns and 
trends in the results rather than arbitrary cutoffs. The 
results of the WOMAN trial have therefore widely been 
accepted as showing a high probability of a clinically 
important reduction in death from bleeding, despite the 
95% CIs reaching 1·00.
Tranexamic acid is unlikely to be effective for all 
causes of postpartum haemorrhage—its main benefit is 
probably for a subgroup of women with a deadly form 
of ongoing or delayed postpartum haemorrhage. But 
postnatal trickling and oozing is not uncommon and is 
often initially missed clinically.7 These lacerations lead 
to a high morbidity and, until now, there has been no 
effective medical therapy. But now we have tranexamic 
acid, which, on its own, prevents over a third of all 
laparotomies for bleeding and a fifth of all deaths from 
postpartum haemorrhage. No wonder the evidence for 
tranexamic acid has been so enthusiastically received by 
clinicians and public health experts in both high‑income 
and low‑income settings. Tranexamic acid might not be 
the so‑called magic bullet that we have all been looking 
for—uterotonics, emergency transport, safe surgery, 
and blood trans fusion are all at least as important for 
reduction of maternal mortality—but it is a welcome 
addition to the armoury. And its widespread introduction 
will save many lives throughout the world every year.
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